The role of HSP27 in the development of drug resistance of gastrointestinal malignancies: Current status and perspectives. Issue 6 (23rd November 2018)

• Record Type: Journal Article
• Authors: Soleimani, Atena; Jalili‐Nik, Mohammad; Avan, Amir; Ferns, Gordon A.; Khazaei, Majid; Hassanian, Seyed Mahdi
• Is Part Of: Journal of cellular physiology. Volume 234:Issue 6(2019:Jun.)
• Page Start: 8241
• Page End: 8248
• Publication Date: 2018-11-23
• Subjects: drug resistance -- gastrointestinal malignancies -- heat‐shock protein 27 -- survival; Physiology -- Periodicals; Cell physiology -- Periodicals; 571.6
• DOI: 10.1002/jcp.27666
• Languages: English
• ISSNs: 0021-9541

Abstract

Abstract: Heat‐shock protein 27 (HSP27) is a chaperone molecule that plays a critical role in the refolding and activity of several proteins responsible for cancer cell drug toxicity. Upregulation of HSP27 is associated with decreased drug sensitivity as well as poorer survival in gastrointestinal (GI) malignancies. It is, therefore, possible that HSP27 may be of value in the assessment of prognostic and therapeutic efficacy in the treatment of GI cancers. Pharmacological and biological inhibitors of HSP27 enhance tumor cell chemosensitivity. This review summarizes the potential role of HSP27 in chemotherapy drug resistance and the therapeutic potential of HSP27 inhibitors as a novel strategy in the treatment of GI cancers. Abstract : Upregulation of heat‐shock protein 27 (HSP27) is associated with decreased drug sensitivity as well as poorer survival in gastrointestinal (GI) malignancies. This review summarizes the potential role of HSP27 in chemotherapy drug resistance, and the therapeutic potential of HSP27 inhibitors as a novel strategy in the treatment of GI cancers.